Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control
(2014)
Journal Article
Glynne-Jones, R., Counsell, N., Quirke, P., Mortensen, N., Maraveyas, A., Meadows, H. M., …Sebag-Montefiore, D. (2014). Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 25(7), 1356-1362. https://doi.org/10.1093/annonc/mdu147
Background: In stage III colon cancer, oxaliplatin/5-fluorouracil (5-FU)-based adjuvant chemotherapy (FOLFOX) improves disease-free survival (DFS) and overall survival (OS). In rectal adenocarcinoma following neoadjuvant chemoradiation (CRT), we exam... Read More about Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.